Pharmacokinetics of meropenem (ICI 194,660) and its metabolite (ICI 213,689) in healthy subjects and in patients with renal impairment.
The pharmacokinetics of meropenem (ICI 194,660) and its open-ring metabolite (ICI 213,689) were studied in 6 healthy volunteers and 16 patients with moderate to severe renal impairment after a single intravenous dose of 500 mg given as a 30-min infusion. Concentrations of unchanged meropenem in plasma and urine were measured by both microbiological and high-pressure liquid chromatographic (HPLC) assays. A good correlation was found between the two techniques. Pharmacokinetic parameters of unchanged meropenem were determined by using the HPLC data. The terminal half-life of unchanged meropenem increased in relation to the degree of renal impairment, being 1.2 h in subjects with normal renal function and 10 h in patients with end-stage renal failure. Total body clearance and renal clearance of unchanged meropenem are linearly related to creatinine clearance. The concentrations of the metabolite in plasma, which are very low in healthy subjects, significantly increased in uremic patients. The apparent half-life of ICI 213,689 increased in uremic patients and was about 35 h in patients with severe renal insufficiency. Meropenem and its metabolite are effectively removed by hemodialysis. The dialysis clearance of the unchanged drug was 81 +/- 22 ml/min. Dosage adjustments of meropenem will be necessary in patients with severe renal impairment.
Leroy
A
A
Department of Biochemistry, University of Rouen, Hôpital Charles Nicolle, France.
Fillastre
J P
JP
Borsa-Lebas
F
F
Etienne
I
I
Humbert
G
G
D000328:Adult; D006801:Humans; D007674:Kidney Diseases / Q000378:metabolism*; D000077731:Meropenem; D008875:Middle Aged; D011758:Pyrroles / Q000493:pharmacokinetics*; D006435:Renal Dialysis; D013845:Thienamycins / Q000493:pharmacokinetics*; D014511:Uremia / Q000378:metabolism
D011758:Pyrroles; D013845:Thienamycins; C069520:ICI 213689; D000077731:Meropenem